Onconova Therapeutics Inc. (NASDAQ:ONTX) fell 2.2% on Monday . The company traded as low as $3.40 and last traded at $3.53, with a volume of 546,330 shares trading hands. The stock had previously closed at $3.61.

Separately, Maxim Group set a $6.00 price objective on Onconova Therapeutics and gave the company a “buy” rating in a research note on Thursday, August 11th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Onconova Therapeutics presently has an average rating of “Buy” and an average price target of $24.74.

The company’s market capitalization is $9.67 million. The stock’s 50-day moving average price is $4.28 and its 200-day moving average price is $4.79.

Onconova Therapeutics (NASDAQ:ONTX) last posted its earnings results on Monday, August 15th. The biopharmaceutical company reported ($1.96) earnings per share (EPS) for the quarter. The company earned $2.25 million during the quarter. Equities research analysts anticipate that Onconova Therapeutics Inc. will post ($7.40) EPS for the current year.

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways important to cancer cells. It has three clinical-stage product candidates and many preclinical programs that target kinases, cellular metabolism or cell division.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.